COLDPLASMATECH GmbH

COLDPLASMATECH GmbH develops innovative wound healing solutions utilizing patented cold plasma technology to enhance treatment effectiveness for chronic wounds. The company's flagship product, the CPT®patch, demonstrates significant advancements in wound care. COLDPLASMATECH GmbH specializes in advanced wound healing technologies, primarily through its CPT®patch product. Founded in Greifswald, Germany in 2015 by Carsten Mahrenholz, who has a background in medical technology, the company has made strides in the healthcare sector.

COLDPLASMATECH GmbH secured venture funding from CreoVis GmbH in March 2017. COLDPLASMATECH specializes in innovative wound healing solutions, primarily through its flagship product, the CPT®patch, which utilizes patented Active Glow® technology to deliver cold, physical plasma directly to wounds. This active wound dressing is designed for the treatment of chronic wounds, including diabetic foot syndrome, pressure ulcers, and severe burns. The CPT®patch works by stimulating wound healing and effectively killing harmful bacteria, including multi-resistant strains, thus addressing significant complications associated with wound care.

The therapy integrates seamlessly into established clinical protocols, making it suitable for a variety of healthcare settings. Coldplasmatech's products are primarily distributed in Germany but are also marketed across Europe, targeting hospitals, outpatient clinics, and specialized wound care centers that cater to millions of patients suffering from chronic and hard-to-heal wounds. COLDPLASMATECH generates revenue through direct sales of its CPT®patch and associated equipment, such as the CPT®cube, to healthcare providers, including hospitals and specialized treatment centers. The transaction structure is primarily B2B, with healthcare facilities purchasing the products under agreements that may include bulk ordering or supply contracts for their wound treatment departments.

The CPT®patch is positioned as a premium medical device, reflecting its advanced technology and effectiveness in accelerating wound healing. Pricing structures are established based on the specific needs of healthcare providers and patient volume, enhancing accessibility to this innovative treatment for chronic wounds. The company’s focus on quality and clinical efficacy helps to build long-term relationships with clients, ensuring ongoing revenue through repeat purchases and potential expansions into new healthcare facilities. COLDPLASMATECH GmbH plans to expand its product line with new innovations targeting advanced wound care solutions, with releases anticipated within the next two years.

The company aims to penetrate additional European markets and is specifically focusing on expanding into the UK and France by 2025. The recent funding round in March 2017 will support these initiatives, enhancing product development and market entry strategies.